Providence’s commitment to patient safety is a high priority among caregivers and that has been recognized by the Oregon Patient Safety Commission. All eight Providence hospitals in Oregon and Providence’s Center for Medically Fragile Children, a residential care facility for young people, were recognized by the commission for meeting an assortment of patient safety targets.
More than 150 people took part as Providence Cancer Center participated in Vice President Biden’s Cancer Moonshot Summit. The goal is to make a decade worth of advances toward a cure in five years, from increasing access to treatment and improving care to freeing trapped data and unleashing new breakthroughs.
An increased focus on compassionate care work means the long-term program director of Providence Portland Medical Center’s internal medicine residency program will step aside, bringing new, but well-known, leadership to the group.
Researchers at Providence Cancer Center received a $75,000 grant to study biomarkers that may help predict responses to immuntherapy and assist oncologists in making treatment-related decisions for patients with head and neck cancers.
Providence Oral, Head and Neck Cancer Clinics now serve patients at two locations: Providence Portland Medical Center and a newly opened clinic at Providence St. Vincent Medical Center.
Providence Cancer Center researchers have initiated several important clinical trials to investigate the effectiveness of promising new immunotherapies to treat patients with head and neck cancers.
Providence is adding oral/dental oncology facilities at Providence Portland and Providence St. Vincent Medical Centers.
Research led by Providence Health & Services has found Medicaid coverage results in significantly higher rates of several common cancer screenings, especially among women. Cancer screenings are often the best way to catch cancer early, resulting in better outcomes and survival rates.
Providence researchers have identified an immunotherapy approach that synergizes with radiation so well it not only eliminated the tumor in most preclinical models with pancreatic cancer, it found and destroyed distant, cancer cells – which could have grown into lethal metastatic tumors.
Providence Cancer Center researchers might have identified how to determine if a patient with advanced melanoma will likely respond to a certain immunotherapy treatment.